Jonathan Treherne
Chairman bij NeuroSolutions Ltd.
Profiel
Jonathan Mark Treherne is the founder of Cambridge Drug Discovery Holdings Ltd.
(founded in 1997) and Ampika Ltd.
(founded in 2003).
He is also the founder of Gen2 Neuroscience Ltd.
(founded in 2016).
Dr. Treherne's current jobs include being the Non-Executive Chairman of NeuroSolutions Ltd.
since 2002, the Non-Executive Chairman of Cyclofluidic Ltd., the Chairman of Ubiquigent Ltd.
since 2013, the Chairman of Talisman Therapeutics Ltd., the Chairman of NuVision Biotherapies Ltd.
since 2018, the Chairman of Monument Therapeutics Ltd., a Non-Executive Director of Domain Therapeutics SA since 2008, a Non-Executive Director of Avilex Pharma ApS, a Director of Spliceor Ltd., and a Professor at the University of Kentucky.
His former jobs include being the Chief Executive Officer of Senexis Ltd., the Non-Executive Chairman of OncoSil Medical Ltd.
from 2005 to 2010, the Chairman of Polpharma Biologics Utrecht BV, a Non-Executive Director of Population Genetics Technologies Ltd., a Director of Acidophil LLC, a Director of Pharmasum Therapeutics AS, a Principal at Pfizer Inc., and a Principal at the University of Basel.
Dr. Treherne obtained a doctorate degree from the University of Cambridge in 1987 and an undergraduate degree from the University of St. Andrews in 1983.
Dr. Treherne is also the founder of Xention Pharma Ltd...
Actieve functies van Jonathan Treherne
Bedrijven | Functie | Begin |
---|---|---|
NeuroSolutions Ltd.
NeuroSolutions Ltd. Miscellaneous Commercial ServicesCommercial Services NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million. | Chairman | 01-03-2002 |
University of Kentucky | Corporate Officer/Principal | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director/Board Member | 01-01-2008 |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | Chairman | 18-09-2013 |
Cyclofluidic Ltd.
Cyclofluidic Ltd. Miscellaneous Commercial ServicesCommercial Services Cyclofluidic Ltd. is a British private company. The firm operates proprietary microfluidic drug discovery platform. | Chairman | - |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | Chairman | - |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | Chairman | 01-01-2018 |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | Chairman | - |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Eerdere bekende functies van Jonathan Treherne
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Opleiding van Jonathan Treherne
University of Cambridge | Doctorate Degree |
University of St. Andrews | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
PFIZER, INC. | Health Technology |
ONCOSIL MEDICAL LIMITED | Health Technology |
Bedrijven in privébezit | 18 |
---|---|
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | Health Technology |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
Cambridge Drug Discovery Holdings Ltd.
Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a private company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Commercial Services |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
NeuroSolutions Ltd.
NeuroSolutions Ltd. Miscellaneous Commercial ServicesCommercial Services NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million. | Commercial Services |
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Commercial Services |
Population Genetics Technologies Ltd.
Population Genetics Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Population Genetics Technologies Ltd. offers population genetics. The firm develops and patents technologies that find, characterize and quantify true genetic variants responsible for disease, disease resistance and drug response for agricultural biotechnology, infectious disease and cancer markets. The company was founded by Sydney Brenner, Sam Eletr, Philip Goelet and Nobel Laureate on April 30, 2004 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Ampika Ltd.
Ampika Ltd. Drugstore ChainsRetail Trade Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom. | Retail Trade |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | Health Services |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Health Technology |
Cyclofluidic Ltd.
Cyclofluidic Ltd. Miscellaneous Commercial ServicesCommercial Services Cyclofluidic Ltd. is a British private company. The firm operates proprietary microfluidic drug discovery platform. | Commercial Services |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | Health Technology |
Gen2 Neuroscience Ltd.
Gen2 Neuroscience Ltd. Pharmaceuticals: GenericHealth Technology Gen2 Neuroscience Ltd. develops novel treatments for dementia targeting abnormal forms of the essential cellular protein tau. The company was founded by Frederick John Livesey in January 07, 2016 and is headquartered in Manchester, the United Kingdom. | Health Technology |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
Pharmasum Therapeutics AS
Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Health Technology |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | Health Technology |
Spliceor Ltd.
Spliceor Ltd. BiotechnologyHealth Technology Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow. | Health Technology |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | Commercial Services |